Premium
HLA class II and response to interferon‐beta in multiple sclerosis
Author(s) -
Fernández O.,
Fernández V.,
Mayorga C.,
Guerrero M.,
León A.,
Tamayo J. A.,
Alonso A.,
Romero F.,
Leyva L.,
Alonso A.,
Luque G.,
Ramón E.
Publication year - 2005
Publication title -
acta neurologica scandinavica
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.967
H-Index - 95
eISSN - 1600-0404
pISSN - 0001-6314
DOI - 10.1111/j.1600-0404.2005.00415.x
Subject(s) - multiple sclerosis , human leukocyte antigen , medicine , genotype , interferon beta , beta (programming language) , immunology , expanded disability status scale , interferon beta 1a , antigen , biology , gene , genetics , computer science , programming language
Objective – To study the relationship between human leucocyte antigen (HLA) genotype and clinical response to interferon‐beta (IFN‐ β ). Methods – We analysed the HLA class II genotypes of 96 multiple sclerosis (MS) patients treated with IFN‐ β . The patients were classified as responders or non‐responders according to clinical criteria: one or more relapses or a sustained increase after 1 year treatment compared with the year prior to IFN‐ β therapy of ≥0.5 points on the Expanded Disability Status Scale (EDSS). Results – There were 66 (69%) responders and 30 (31%) non‐responders. Baseline clinical characteristics were similar. We found no association between HLA class II alleles and clinical response to IFN‐ β . Conclusions – HLA genotype does not appear to influence the clinical response to IFN‐ β in MS patients.